Fig. 5: Synergistic activity of venetoclax and azacytidin on PML::RARA+ cells.
A Apoptosis was assessed by flow cytometry using propidium iodide (PI) staining to measure sub-G1 DNA content, which reflects the population of cells undergoing DNA fragmentation—a hallmark of late apoptosis. This analysis was performed on blast cells from one APL patient, either untreated or treated with Azacitidine (AZA) and Venetoclax (VTX) for 48 h. B Two dimension (2D) and 3D synergy map for the combination of VTX (0 to 300 nM) and AZA (0 to 1000 ng/ml) analyzing cell grow by MTT assay. Data represent two independent biological replicates performed in MT and PR9 (PML::RARα+) cells. The ZIP score (∂-score) for each drug combination is indicated by the color code given above the panel grid (synergistic and antagonistic dose regions in red and green colors, respectively). C Two dimension (2D) and 3D synergy map for the combination of VTX (0 to 300 nM) and AZA (0 to 1000 ng/ml) plus NH4Cl, analyzing cell grow by MTT assay. Data represent two independent biological replicates performed in MT and PR9 (PML::RARα+) cells. The ZIP score (∂-score) for each drug combination is indicated by the color code given above the panel grid (synergistic and antagonistic dose regions in red and green colors, respectively). ZIP score >10 indicates synergism; ZIP score between -10 and 10 indicates additivity; and ZIP score <-10 indicates antagonism. The panels were obtained by Synergy Finder analysis (https://synergyfinder.fimm.fi/synergy/synfin_docs/).
